e-learning
resources
ERJ
2011
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
A 5-aza-2?-deoxycytidine/valproate combination induces cytotoxic T-cell response against mesothelioma
Leclercq S., Gueugnon F., Boutin B., Guillot F., Blanquart C., Rogel A., Padieu M., Pouliquen D., Fonteneau J-F., Grégoire M.
Source:
Eur Respir J 2011; 38: 1105-1116
Journal Issue:
November
Disease area:
Thoracic oncology
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
Leclercq S., Gueugnon F., Boutin B., Guillot F., Blanquart C., Rogel A., Padieu M., Pouliquen D., Fonteneau J-F., Grégoire M.. A 5-aza-2?-deoxycytidine/valproate combination induces cytotoxic T-cell response against mesothelioma. Eur Respir J 2011; 38: 1105-1116
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Diagnosis and staging of malignant pleural mesothelioma
Combination therapy in the era of immunotherapy
Cisplatin/pemetrexed chemotherapy versus palliative care survival in malignant pleural mesothelioma
Related content which might interest you:
Suberoylanilide hydroxamic acid: a potential epigenetic therapeutic agent for lung fibrosis?
Source: Eur Respir J 2009; 34: 145-155
Year: 2009
Valproate–doxorubicin: promising therapy for progressing mesothelioma. A phase II study
Source: Eur Respir J 2011; 37: 129-135
Year: 2011
Valproic acid improves second-line regimen of small cell lung carcinoma in preclinical models
Source: ERJ Open Res 2015; 1: 00028-2015
Year: 2015
Comparison of anticancer effects of a novel histone deacetylase (HDAC) inhibitor CG200745 and SAHA in non-small lung cancer cells
Source: International Congress 2019 – Diagnostic procedures and biology of lung cancer
Year: 2019
All-trans-retinoic acid inhibits tumour growth of malignant pleural mesothelioma in mice
Source: Eur Respir J 2009; 34: 1159-1167
Year: 2009
VAC chemotherapy with valproic acid for refractory/relapsing small cell lung cancer: a phase II study
Source: ERJ Open Res 2015; 1: 00029-2015
Year: 2015
Ursodeoxy cholic acid (UDCA) reverses hepatotoxicity of multidrug treatment of mycobacterial infections
Source: International Congress 2018 – Challenges in treating tuberculosis and nontuberculous mycobacteria
Year: 2018
Histone deacetylase inhibition significantly augments human mesothelioma cellular response to chemotherapeutic agents
Source: Eur Respir J 2001; 18: Suppl. 33, 396s
Year: 2001
Folic acid phenotype (FAP) as superior marker to predict pemetrexed response in pleural mesothelioma
Source: International Congress 2016 – Mesothelioma and pleural disease: from the bench to the bedside
Year: 2016
Synergistic anti-tumor effects of vandetanib, an inhibitor of VEGFR and EGFR tyrosine kinase inhibitor, combined with cytotoxic agents in lung cancer cell lines
Source: Annual Congress 2010 - Treatment of lung cancer
Year: 2010
Recognition of pleural mesothelioma by mucin-1(950–958)/human leukocyte antigen A*0201-specific CD8+ T-cells
Source: Eur Respir J 2011; 38: 1117-1126
Year: 2011
2-Deoxy-glucose synergizes with Cisplatin and Pemetrexed chemotherapeutics to reduce cell migration of mesothelioma cells
Source: International Congress 2019 – Pleural disease: applying the evidence
Year: 2019
Novel anti-angiogenic pharmacotherapy strategies
Source: Annual Congress 2005 - Update on the role of angiogenesis in the pathogenesis and treatment of lung diseases
Year: 2005
In vitro
and
vivo
study of isoxyl, a mycolic acid inhibitor for intermittent chemotherapy of multi drug resistant (MDR) strains of
mycobacterium tuberculosis
(M.tb)
Source: Eur Respir J 2006; 28: Suppl. 50, 587s
Year: 2006
Rosmarinic acid enhances apoptosis and cell cycle arrest induced by Carnosic acid on Human Lung Fibroblasts
Source: International Congress 2017 – Rare diseases
Year: 2017
Differential actions of the endogenous docosahexaenoic acid (DHA) electrophilic derivative 17-oxo-DHA in macrophages and bronchial epithelial cells
Source: Annual Congress 2013 –The pulmonary epithelium: recent developments
Year: 2013
Retinoic acid induces alveolar regeneration in the adult mouse lung
Source: Eur Respir J 2004; 23: 20-27
Year: 2004
Emerging prognostic biomarkers in non small cell lung cancer patients: Impact of treatment with nimesulide (COX-2 inhibitor) combined with chemotherapy
Source: Annual Congress 2011 - Biomarkers and other new methods for lung cancer
Year: 2011
The role of fibrocyte-like cells in combination treatment of immune checkpoint inhibitor with antiangiogenic agents
Source: Virtual Congress 2020 – Novel directions in pleural disease: bench to bedside
Year: 2020
Stimulation with polyinosinic-polycytidylic acid (poly(I:C)) encapsulated within novel pH-sensitive switchable liposomes leads to a faster and more potent interferon response
Source: International Congress 2016 – Pulmonary drug delivery
Year: 2016
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept